Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy

    Journal of the American Society of Nephrology Date published:

  • A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)

    Journal of the American Society of Nephrology Date published:

  • On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D

    Journal of the American Society of Nephrology Date published:

  • Gene Polymorphism in Organic Anion Transporters Determine the Long-Term Efficacy and Safety of Atrasentan in Patients With Type 2 Diabetes and CKD

    Journal of the American Society of Nephrology Date published:

  • Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD

    Journal of the American Society of Nephrology Date published:

  • Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice

    Heart, Lung and Circulation Date published:

  • Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

    Journal of the American College of Cardiology Date published:

  • Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

    The Lancet Date published:

  • Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials

    European Heart Journal Date published:

  • Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

    European Heart Journal Date published:

  • Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

    European Heart Journal Date published:

  • Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

    Cardiovascular Diabetology Date published:

  • Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy-Reply

    JAMA Date published:

  • Abstract P201: Canagliflozin, Visit-to-visit Blood Pressure Variability, And Risk Of Cardiovascular, Kidney, And Mortality Outcomes: Pooled Individual Participant Data From The CANVAS And CREDENCE Trials

    Hypertension Date published:

  • Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Diabetes Care Date published:

  • Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria

    Expert Review of Clinical Pharmacology Date published: